Company Performance Metrics
Atonco develops targeted alpha radiopharmaceuticals for oncology. The company designs astatine‑211 labeled candidates that aim to deliver alpha radiation directly to tumor cells while limiting exposure to healthy tissue. Its activities include ligand discovery, radiochemistry optimization, preclinical evaluation, and preparation for clinical
studies. Atonco also builds processes for isotope sourcing, labeling, and quality control to support future clinical supply. Collaborations with academic and clinical centers help validate targets and imaging strategies for theranostic pairs. The pipeline focuses on solid tumors where high linear energy transfer may address resistance to standard treatments. Information for partners and investigators covers candidate status, manufacturing approaches, and data from pharmacology and dosimetry studies.
